The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B

Overview

Journal Sci Rep

Specialty Science

Date 2016 Feb 24

PMID 26902995

Citations 90

Authors

Shaoyong Lu

Hyunbum Jang

Ruth Nussinov

Jian Zhang

Affiliations

Soon will be listed here.

Abstract

Ras mediates cell proliferation, survival and differentiation. Mutations in K-Ras4B are predominant at residues G12, G13 and Q61. Even though all impair GAP-assisted GTP → GDP hydrolysis, the mutation frequencies of K-Ras4B in human cancers vary. Here we aim to figure out their mechanisms and differential oncogenicity. In total, we performed 6.4 μs molecular dynamics simulations on the wild-type K-Ras4B (K-Ras4B(WT)-GTP/GDP) catalytic domain, the K-Ras4B(WT)-GTP-GAP complex, and the mutants (K-Ras4B(G12C/G12D/G12V)-GTP/GDP, K-Ras4B(G13D)-GTP/GDP, K-Ras4B(Q61H)-GTP/GDP) and their complexes with GAP. In addition, we simulated 'exchanged' nucleotide states. These comprehensive simulations reveal that in solution K-Ras4B(WT)-GTP exists in two, active and inactive, conformations. Oncogenic mutations differentially elicit an inactive-to-active conformational transition in K-Ras4B-GTP; in K-Ras4B(G12C/G12D)-GDP they expose the bound nucleotide which facilitates the GDP-to-GTP exchange. These mechanisms may help elucidate the differential mutational statistics in K-Ras4B-driven cancers. Exchanged nucleotide simulations reveal that the conformational transition is more accessible in the GTP-to-GDP than in the GDP-to-GTP exchange. Importantly, GAP not only donates its R789 arginine finger, but stabilizes the catalytically-competent conformation and pre-organizes catalytic residue Q61; mutations disturb the R789/Q61 organization, impairing GAP-mediated GTP hydrolysis. Together, our simulations help provide a mechanistic explanation of key mutational events in one of the most oncogenic proteins in cancer.

Citing Articles

Tumour-agnostic kinase inhibitors.

Adashek J, Nikanjam M, Kurzrock R Nat Rev Drug Discov. 2025; .

PMID: 40050521 DOI: 10.1038/s41573-025-01147-y.

First molecules to reactivate RAS GTPase activity.

Wlodarczyk A, Treda C, Pacholczyk M, Rutkowska A, Wegierska M, Kierasinska-Kalka A BMC Cancer. 2025; 25(1):182.

PMID: 39891136 PMC: 11783748. DOI: 10.1186/s12885-025-13580-8.

Associations of KRAS Point Mutations with Survival of Patients Who Underwent Curative-Intent Resection of Colorectal Liver Metastases.

Maki H, Ayabe R, Haddad A, Nishioka Y, Newhook T, Tran Cao H Ann Surg Oncol. 2025; 32(4):2425-2434.

PMID: 39821490 DOI: 10.1245/s10434-024-16822-4.

Structural Dynamics of Rho GTPases.

Lin Y, Zheng Y J Mol Biol. 2024; 437(3):168919.

PMID: 39708912 PMC: 11757035. DOI: 10.1016/j.jmb.2024.168919.

Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants.

Jani V, Sonavane U, Joshi R Heliyon. 2024; 10(16):e36161.

PMID: 39247361 PMC: 11379609. DOI: 10.1016/j.heliyon.2024.e36161.

References

Alred E, Scheele E, Berhanu W, Hansmann U . Stability of Iowa mutant and wild type Aβ-peptide aggregates. J Chem Phys. 2014; 141(17):175101. PMC: 4241800. DOI: 10.1063/1.4900892. View

Hall B, Bar-Sagi D, Nassar N . The structural basis for the transition from Ras-GTP to Ras-GDP. Proc Natl Acad Sci U S A. 2002; 99(19):12138-42. PMC: 129411. DOI: 10.1073/pnas.192453199. View

Lu S, Li S, Zhang J . Harnessing allostery: a novel approach to drug discovery. Med Res Rev. 2014; 34(6):1242-85. DOI: 10.1002/med.21317. View

Prior I, Lewis P, Mattos C . A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012; 72(10):2457-67. PMC: 3354961. DOI: 10.1158/0008-5472.CAN-11-2612. View

Cox A, Fesik S, Kimmelman A, Luo J, Der C . Drugging the undruggable RAS: Mission possible?. Nat Rev Drug Discov. 2014; 13(11):828-51. PMC: 4355017. DOI: 10.1038/nrd4389. View

Araki M, Shima F, Yoshikawa Y, Muraoka S, Ijiri Y, Nagahara Y . Solution structure of the state 1 conformer of GTP-bound H-Ras protein and distinct dynamic properties between the state 1 and state 2 conformers. J Biol Chem. 2011; 286(45):39644-53. PMC: 3234787. DOI: 10.1074/jbc.M111.227074. View

Gkeka P, Evangelidis T, Pavlaki M, Lazani V, Christoforidis S, Agianian B . Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. PLoS Comput Biol. 2014; 10(10):e1003895. PMC: 4207468. DOI: 10.1371/journal.pcbi.1003895. View

Hunter J, Gurbani D, Ficarro S, Carrasco M, Lim S, Choi H . In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A. 2014; 111(24):8895-900. PMC: 4066474. DOI: 10.1073/pnas.1404639111. View

Kumar A, Glembo T, Ozkan S . The Role of Conformational Dynamics and Allostery in the Disease Development of Human Ferritin. Biophys J. 2015; 109(6):1273-81. PMC: 4576160. DOI: 10.1016/j.bpj.2015.06.060. View

10.

Ford B, Hornak V, Kleinman H, Nassar N . Structure of a transient intermediate for GTP hydrolysis by ras. Structure. 2006; 14(3):427-36. DOI: 10.1016/j.str.2005.12.010. View

11.

Lu S, Jang H, Zhang J, Nussinov R . Inhibitors of Ras-SOS Interactions. ChemMedChem. 2015; 11(8):814-21. DOI: 10.1002/cmdc.201500481. View

12.

Kotting C, Kallenbach A, Suveyzdis Y, Wittinghofer A, Gerwert K . The GAP arginine finger movement into the catalytic site of Ras increases the activation entropy. Proc Natl Acad Sci U S A. 2008; 105(17):6260-5. PMC: 2359817. DOI: 10.1073/pnas.0712095105. View

13.

Invernizzi G, Tiberti M, Lambrughi M, Lindorff-Larsen K, Papaleo E . Communication routes in ARID domains between distal residues in helix 5 and the DNA-binding loops. PLoS Comput Biol. 2014; 10(9):e1003744. PMC: 4154638. DOI: 10.1371/journal.pcbi.1003744. View

14.

Resat H, Straatsma T, Dixon D, Miller J . The arginine finger of RasGAP helps Gln-61 align the nucleophilic water in GAP-stimulated hydrolysis of GTP. Proc Natl Acad Sci U S A. 2001; 98(11):6033-8. PMC: 33417. DOI: 10.1073/pnas.091506998. View

15.

Nussinov R, Jang H, Tsai C . The structural basis for cancer treatment decisions. Oncotarget. 2014; 5(17):7285-302. PMC: 4202123. DOI: 10.18632/oncotarget.2439. View

16.

Ma J, Karplus M . Molecular switch in signal transduction: reaction paths of the conformational changes in ras p21. Proc Natl Acad Sci U S A. 1997; 94(22):11905-10. PMC: 23651. DOI: 10.1073/pnas.94.22.11905. View

17.

Cherfils J, Zeghouf M . Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev. 2013; 93(1):269-309. DOI: 10.1152/physrev.00003.2012. View

18.

Ekhteiari Salmas R, Yurtsever M, Durdagi S . Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations. Sci Rep. 2015; 5:13180. PMC: 4547396. DOI: 10.1038/srep13180. View

19.

Jang H, Banerjee A, Chavan T, Lu S, Zhang J, Gaponenko V . The higher level of complexity of K-Ras4B activation at the membrane. FASEB J. 2016; 30(4):1643-55. PMC: 4799498. DOI: 10.1096/fj.15-279091. View

20.

Rudack T, Xia F, Schlitter J, Kotting C, Gerwert K . Ras and GTPase-activating protein (GAP) drive GTP into a precatalytic state as revealed by combining FTIR and biomolecular simulations. Proc Natl Acad Sci U S A. 2012; 109(38):15295-300. PMC: 3458370. DOI: 10.1073/pnas.1204333109. View